Paxlovid, the most commonly prescribed at home treatment for COVID-19 in the US, will remain available for free to patients there until the end of the year, Pfizer said. 

In Pfizer’s clinical trial, Paxlovid was shown to reduce hospitalizations and death by around 90% for unvaccinated people at risk for serious disease.

In another trial, Pfizer was not able to show benefit for those considered at standard risk, including vaccinated patients.